Purple Biotech appoints Isaac Israel interim CEO as Gil Efron steps down

Bitget2026/10/05 20:39

Purple Biotech appointed director Isaac Israel as interim CEO effective Oct. 5, 2026, pending selection of a permanent chief executive. Israel previously served as CEO from Oct. 2012 to July 2022, advised the company since Oct. 2022, led as acting CEO March–August 2023. He previously ran BeeContact as founding CEO from 2001 to 2007, later founded Uneri Capital, a capital markets and healthcare consultancy. Outgoing CEO Gil Efron will shift to executive director, head of corporate development effective Oct. 5, 2026, while remaining on the board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106852), on October 05, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Purple Biotech appointed director Isaac Israel as interim CEO effective Oct. 5, 2026, pending selection of a permanent chief executive.
Israel previously served as CEO from Oct. 2012 to July 2022, advised the company since Oct. 2022, led as acting CEO March–August 2023.
He previously ran BeeContact as founding CEO from 2001 to 2007, later founded Uneri Capital, a capital markets and healthcare consultancy.
Outgoing CEO Gil Efron will shift to executive director, head of corporate development effective Oct. 5, 2026, while remaining on the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106852), on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26